Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous N-acetylcysteine (NAC) for Prevention of Post-embolization Syndrome in Hepatocellular Carcinoma
TCTR20150313002Phase 3Enrolling by invitation
- Sponsor
- Thammasat University
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of acetylcysteine in hepatocellular carcinoma (HCC), post-embolization syndrome (PES), sponsored by Thammasat University. Started Feb 2015; status: enrolling by invitation.
02
Drugs
acetylcysteine
03
Conditions
hepatocellular carcinoma (HCC)post-embolization syndrome (PES)
Beyond the preview
Go deeper on TCTR20150313002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20150313002.